首页 | 本学科首页   官方微博 | 高级检索  
     

大白鼠皮下植入米非司酮埋植剂血药浓度和抑制异位子宫内膜效果的观察
引用本文:王林,于祖茹,刘佩芳,唐丽娜,武莉,宋存先,孙洪范. 大白鼠皮下植入米非司酮埋植剂血药浓度和抑制异位子宫内膜效果的观察[J]. 生物医学工程与临床, 2008, 12(2): 97-100
作者姓名:王林  于祖茹  刘佩芳  唐丽娜  武莉  宋存先  孙洪范
作者单位:1. 天津市人民医院外科
2. 天津市中心妇产科医院,天津,300052
3. 天津医科大学,肿瘤医院,放射科,天津,300060
4. 中国医学科学院,中国协和医科大学,生物医学工程研究所,天津市生物医学材料重点实验室,天津,300192
摘    要:目的观察大鼠皮下植入米非司酮埋植剂后的血药浓度变化及抑制大鼠子宫内膜异位症的效果。方法取体质量170~190g Wister雌性正常大鼠,分别在正常大鼠和动物模型大鼠(实验组5组和对照组)皮下埋植单根0.75cm、1.5cm、3.0cm和2根、3根3cm长米非司酮埋植剂(外径2.5mm),对照组植入2根3.0cm不含药的埋植剂。正常大鼠给药1个月.定期取血用HPLC法测血药浓度。动物模型大鼠给药3个月.用MRI测定异位子宫内膜体积并计算抑制率。结果不同剂量的米非司酮皮下埋植剂皆在植入体内7d时,血药浓度达到最高:随着给药剂量加大,血药浓度峰值也趋向增高,但7d后血药浓度逐渐下降,14d后除3根剂量组的血药浓度显著较高外(约0.18~0.20μg/ml),其他较低剂量组之间的血药浓度差异无统计学意义(约0.10~0.13μg/ml)。大鼠皮下植入埋植剂的剂量与血药浓度峰值呈线性关系。动物模型皮下植入1根1.5cm、3.0cm或2根3.0cm长埋植剂1个月时,异位内膜抑制率分别为18.6%±17.3%、31.5%±12.7%、72.2%±12.3%,与对照组比较差异有统计学意义,并且不再随剂量加大而显著提高抑制效果。结论 米非司酮皮下埋植剂作为治疗子宫内膜异位症的长效制剂是可行的.

关 键 词:子宫内膜异位症  米非司酮  埋植剂  聚己内酯
文章编号:1009-7090(2008)02-0097-04
修稿时间:2007-11-10

Serum mifepristone level and effect of mifepristone-releasing implants on the endometriosis in rats
WANG Lin,YU Zu-ru,LIU Pei-fang,TANG Li-na,WU Li,SONG Cun-xian,SUN Hong-fan. Serum mifepristone level and effect of mifepristone-releasing implants on the endometriosis in rats[J]. Biomedical Engineering and Clinical Medicine, 2008, 12(2): 97-100
Authors:WANG Lin  YU Zu-ru  LIU Pei-fang  TANG Li-na  WU Li  SONG Cun-xian  SUN Hong-fan
Affiliation:WANG Lin ,YU Zu-ru,LIU Pei-fang,TANG Li-na,WU Li ,S0NG Cun-xian ,SUN Hong-fan (1.Institute of Biomedical Engineering, Chinese Academy of Medical Sciences & Peking Union Medical College ,Tianjin 300192,China;2. Tianjin Central Maternity Hospital, Tianjin 300052,China;3.Department of Radiology, Tianjin Medical University of Cancer Institute and Hospital, Tianj in 300060,China)
Abstract:Objective To observe the serum mifepristone levels and the inhibitory effect of mifepristone-releasing implants on the endometriosis in rats. Methods The normal rats and the rats with endometriosls were subdermally implanted a piece of the 0.75,1.5,3.0 cm, 2 or 3 pieces of 3.0 cm lenth of mifepristone-releasing implants resepectively. The serum levels of mlfepristone in normal rats were determined by HPLC. The changes of volumes of explants in rat with endometriosis were measured by MRI at 1,2,3 months after administration. Results The peak concentrations of mifepristone found in all normal rats at the 7th days and increased in proportion to dose. After 7 days, the serum levels of mifepristone decreased gradually. After administration 14 days, the concentrations of serum mifepristone in all normal rats (about 0.10~ 0.13 μg/ml) showed no significant differences with rats implanted 3 pieces of 3.0 cm lenth of mifepristone-releasing implants (about 0.18 ~ 0.20 μg/ml).Administration of 1/2,1,2 pieces of 3.0 cm lenth of mifepristone-releasing implants resulted in inhibitory rates of 18.6 % ± 17.3 %, 31.5 % ± 12.7 % and 72.2 % ± 12.3 % respectively at 1 month. But administration of 3 pieces 3.0 cm lenth of implants,better inhibitory effects were not observed. Conclusion It is demonstrated that subcutaneous administrating mifepristone-releasing implant shows obvious therapautical effect on endometriosis.
Keywords:endometriosis  mifepristone  implant  caprolactone
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号